The CD179a antibody targets CD179a, also known as immunoglobulin alpha (Igα) or CD79a, a key component of the B-cell receptor (BCR) complex. CD179a pairs with CD179b (Igβ or CD79b) to form a heterodimer essential for BCR assembly, surface expression, and signal transduction. Structurally, CD179a contains an extracellular immunoglobulin (Ig)-like domain, a transmembrane region, and a cytoplasmic tail with immunoreceptor tyrosine-based activation motifs (ITAMs). These ITAMs recruit signaling molecules like Syk kinase upon BCR engagement, initiating downstream pathways critical for B-cell development, activation, and antigen response.
CD179a is expressed exclusively during B-cell lineage development, from pro-B to mature B cells, making it a specific marker for B-cell identification. Dysregulation of CD179a-mediated signaling is linked to B-cell malignancies (e.g., leukemia, lymphoma) and autoimmune disorders. Antibodies against CD179a are widely used in research to study BCR dynamics, B-cell maturation defects, and disease mechanisms. In diagnostics, CD179a antibodies help classify B-cell neoplasms via flow cytometry or immunohistochemistry. Therapeutically, they are explored for targeting BCR-positive cancers or modulating aberrant immune responses. However, their clinical application remains experimental, with challenges including specificity and off-target effects. Overall, CD179a antibodies serve as vital tools for unraveling B-cell biology and developing precision therapies.